Filter Results
:
(255)
Show Results For
-
All HBS Web
(1,023)
- Faculty Publications (255)
Show Results For
-
All HBS Web
(1,023)
- Faculty Publications (255)
Drug →
- spring 1996
- Article
Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
Henderson, Rebecca M., and Ian Cockburn. "Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery." RAND Journal of Economics 27, no. 1 (spring 1996): 32–59.
- January 1996
- Case
Biogen, Inc.: rBeta Interferon Manufacturing Process Development
Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing...
View Details
Keywords:
Learning;
Technological Innovation;
Management Analysis, Tools, and Techniques;
Product Development;
Organizational Change and Adaptation;
Projects;
Research and Development;
Corporate Strategy;
Biotechnology Industry
Wheelwright, Steven C. "Biogen, Inc.: rBeta Interferon Manufacturing Process Development." Harvard Business School Case 696-083, January 1996.
- fall 1994
- Article
Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
Henderson, Rebecca M., and Ian Cockburn. "Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery." Journal of Economics & Management Strategy 3, no. 3 (fall 1994): 481–519.
- Article
Measuring Competence? Exploring Firm Effects in Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
Henderson, Rebecca M., and Ian Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Strategic Management Journal 15 (Winter 1994): 63–84. (Winner of Dan and Mary Lou Schendel Best Paper Prize To honor substantial work published in the Strategic Management Journal presented by Strategic Management Society.)
- 1994
- Article
The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery
Henderson, Rebecca M. "The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery." Industrial and Corporate Change 3, no. 3 (1994): 607–630.
- November 1993 (Revised January 2006)
- Supplement
Beech-Nut Nutrition Corporation (B)
By: Lynn S. Paine
Officials of the U.S. Food and Drug Administration (FDA) must decide whether to refer the Beech-Nut apple juice case to the Justice Department for criminal prosecution, and if so, whether to recommend prosecution of individual executives or of the company only.
View Details
Paine, Lynn S. "Beech-Nut Nutrition Corporation (B)." Harvard Business School Supplement 394-103, November 1993. (Revised January 2006.)
- September 1993
- Case
Manufacturing at ALZA: The Right Prescription? (A)
ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner...
View Details
Keywords:
Business or Company Management;
Technological Innovation;
Innovation and Management;
Growth and Development Strategy;
Problems and Challenges;
Production;
Research and Development;
Organizational Change and Adaptation;
Pharmaceutical Industry;
Medical Devices and Supplies Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (A)." Harvard Business School Case 694-019, September 1993.
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (B)
ALZA, a drug delivery company, must decide what and for whom to manufacture. In the past, it has licensed to pharmaceutical companies its patented system for the slow release of drugs into the human system. Therefore the company has little experience in choice of drug...
View Details
Keywords:
Experience and Expertise;
Decision Choices and Conditions;
Patents;
Production;
Pharmaceutical Industry;
Medical Devices and Supplies Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (B)." Harvard Business School Supplement 694-020, September 1993.
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (C)
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company.
View Details
Keywords:
Mergers and Acquisitions;
Product Marketing;
Alliances;
Research and Development;
Salesforce Management;
Business Strategy;
Pharmaceutical Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (C)." Harvard Business School Supplement 694-021, September 1993.
- June 1993
- Case
Boston Fights Drugs
Rangan, V. Kasturi. "Boston Fights Drugs." Harvard Business School Multimedia/Video Case 593-517, June 1993.
- April 1993 (Revised October 1995)
- Case
ALZA and Bio-Electro Systems (A): Technological and Financial Innovation
By: Josh Lerner and Peter Tufano
To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,...
View Details
Keywords:
Risk and Uncertainty;
Technological Innovation;
Business Subsidiaries;
Decision Choices and Conditions;
Corporate Finance;
Biotechnology Industry;
Medical Devices and Supplies Industry
Lerner, Josh, and Peter Tufano. "ALZA and Bio-Electro Systems (A): Technological and Financial Innovation." Harvard Business School Case 293-124, April 1993. (Revised October 1995.)
- March 1993
- Supplement
Burroughs Wellcome and AZT (B)
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy.
View Details
Keywords:
Ethics;
Health Pandemics;
Multinational Firms and Management;
Price;
Crime and Corruption;
Risk and Uncertainty;
Business Strategy;
Business and Community Relations;
Business and Government Relations;
Business and Shareholder Relations;
Pharmaceutical Industry
Emmons, Willis M., III. "Burroughs Wellcome and AZT (B)." Harvard Business School Supplement 793-114, March 1993.
- February 1993 (Revised August 1995)
- Case
Medicare Payment for Drugs and Medical Devices
Keywords:
Health Care and Treatment;
Business and Government Relations;
Medical Devices and Supplies Industry;
Health Industry;
Pharmaceutical Industry
Herzlinger, Regina E. "Medicare Payment for Drugs and Medical Devices." Harvard Business School Case 193-099, February 1993. (Revised August 1995.)
- October 1992 (Revised September 1993)
- Case
Nopane Advertising Strategy
By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results...
View Details
Keywords:
Competition;
Intellectual Property;
Advertising;
Health Care and Treatment;
Brands and Branding;
Product Marketing;
Pharmaceutical Industry;
United States
Bell, David E. "Nopane Advertising Strategy." Harvard Business School Case 893-005, October 1992. (Revised September 1993.)
- March 1992
- Case
Amgen, Inc.: Planning the Unplannable
By: Nitin Nohria
By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and...
View Details
Keywords:
Growth and Development Strategy;
Strategic Planning;
Success;
Risk and Uncertainty;
Pharmaceutical Industry
Nohria, Nitin. "Amgen, Inc.: Planning the Unplannable." Harvard Business School Case 492-052, March 1992.
- September 1991 (Revised August 1994)
- Background Note
Note on Pharmaceutical Industry Regulation
Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,...
View Details
Keywords:
Safety;
Industry Growth;
Marketing;
Research and Development;
Health Testing and Trials;
Economics;
Pharmaceutical Industry;
United States
Emmons, Willis M., III. "Note on Pharmaceutical Industry Regulation." Harvard Business School Background Note 792-002, September 1991. (Revised August 1994.)
- September 1991 (Revised February 1993)
- Case
Burroughs Wellcome and AZT (A)
Burroughs Wellcome Co., developer of AZT, the first drug approved by the U.S. Food and Drug Administration for the treatment of Acquired Immune Deficiency Syndrome (AIDS), finds itself under siege in September 1989 by AIDS activists and various segments of the U.S....
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Ethics;
Business and Government Relations;
Communication Strategy;
Health Care and Treatment;
Monopoly;
Intellectual Property;
Research and Development;
Price;
Pharmaceutical Industry;
London
Emmons, Willis M., III. "Burroughs Wellcome and AZT (A)." Harvard Business School Case 792-004, September 1991. (Revised February 1993.)
- October 1990 (Revised April 1991)
- Case
RU 486 (A)
Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its...
View Details
Keywords:
Judgments;
Ethics;
Product Launch;
Negotiation;
Outcome or Result;
Performance;
Business and Government Relations;
Health Industry;
Pharmaceutical Industry;
France;
Germany;
United States
Badaracco, Joseph L., Jr. "RU 486 (A)." Harvard Business School Case 391-050, October 1990. (Revised April 1991.)
- April 1989 (Revised May 1993)
- Case
Novel Combination of Two Drugs (A)
Herzlinger, Regina E. "Novel Combination of Two Drugs (A)." Harvard Business School Case 189-168, April 1989. (Revised May 1993.)